IDH1 and glioblastoma: They were first identified by Yan et al. in 2009, when they found out that these mutations occurred in most patients with secondary GBM and were associated with an increase in overall survival OS).[17] Nowadays, after subsequent studies regarding this issue, it is agreed that IDH1 mutation is the most reliable diagnostic molecular marker of secondary GBMs.[5]